Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study.
Alberto DelaidelliChristopher DunhamMariarita SantiGian Luca NegriJoanna TriscottOlga ZheludkovaAndrey GolanovMarina RyzhovaKonstantin OkonechnikovDaniel SchrimpfDamian StichelDavid W EllisonAndreas von DeimlingMarcel KoolStefan M PfisterVijay RamsawamiAndrey KorshunovMichael D TaylorPoul H SorensenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
This study redefines the approach to risk stratification in group 3/4 medulloblastoma in global practice. Because integration of TPD52 IHC in classification algorithms significantly improved outcome prediction, this test could be rapidly adopted for risk stratification on a global scale, independently of advanced but technically challenging molecular profiling techniques.